Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acebutolol hydrochloride
Drug ID BADD_D00020
Description A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Indications and Usage For the management of hypertension and ventricular premature beats in adults.
Marketing Status Prescription; Discontinued
ATC Code C07AB04
DrugBank ID DB01193
KEGG ID D00597
MeSH ID D000070
PubChem ID 441307
TTD Drug ID D0HD9K
NDC Product Code 53746-670; 10135-630; 52932-0719; 65162-670; 51927-2906; 50268-050; 65162-669; 68069-0009; 58159-081; 10135-631; 53746-669
Synonyms Acebutolol | Acetobutolol | Acebutolol Hydrochloride | M&B-17803 A | M&B 17803 A | M&B17803 A | M & B 17803A | Neptal | Prent | Rhotral | Sectral | Monitan | Apo-Acebutolol | Apo Acebutolol | ApoAcebutolol | Novo-Acebutolol | Novo Acebutolol | NovoAcebutolol
Chemical Information
Molecular Formula C18H29ClN2O4
CAS Registry Number 34381-68-5
SMILES CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eye pain06.08.03.002--
Fatigue08.01.01.002--
Flatulence07.01.04.002--
Headache17.14.01.001--
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.002--
Insomnia19.02.01.002; 17.15.03.002--
Laryngospasm22.04.02.002--
Malaise08.01.01.003--
Mesenteric artery thrombosis24.01.08.003; 07.15.02.008--Not Available
Micturition disorder20.02.02.005--Not Available
Myalgia15.05.02.001--
Nausea07.01.07.001--
Nocturia20.02.03.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Peyronie's disease21.12.01.002--Not Available
Pharyngitis11.01.13.003; 22.07.03.004; 07.05.07.004--
Pruritus23.03.12.001--
Psychomotor hyperactivity19.11.02.003; 17.01.02.011--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.06.003--Not Available
Respiratory distress22.02.01.012--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Performance status decreased08.01.03.042--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages